• Je něco špatně v tomto záznamu ?

Pathogenic postzygotic mosaicism in the tyrosine receptor kinase pathway: potential unidentified human disease hidden away in a few cells

I. Tiemann-Boege, T. Mair, A. Yasari, M. Zurovec

. 2021 ; 288 (10) : 3108-3119. [pub] 20200905

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025784
E-zdroje Online Plný text

NLK Free Medical Journals od 2005 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Wiley Free Content od 2005 do Před 1 rokem

Mutations occurring during embryonic development affect only a subset of cells resulting in two or more distinct cell populations that are present at different levels, also known as postzygotic mosaicism (PZM). Although PZM is a common biological phenomenon, it is often overlooked as a source of disease due to the challenges associated with its detection and characterization, especially for very low-frequency variants. Moreover, PZM can cause a different phenotype compared to constitutional mutations. Especially, lethal mutations in receptor tyrosine kinase (RTK) pathway genes, which exist only in a mosaic state, can have completely new clinical manifestations and can look very different from the associated monogenic disorder. However, some key questions are still not addressed, such as the level of mosaicism resulting in a pathogenic phenotype and how the clinical outcome changes with the development and age. Addressing these questions is not trivial as we require methods with the sensitivity to capture some of these variants hidden away in very few cells. Recent ultra-accurate deep-sequencing approaches can now identify these low-level mosaics and will be central to understand systemic and local effects of mosaicism in the RTK pathway. The main focus of this review is to highlight the importance of low-level mosaics and the need to include their detection in studies of genomic variation associated with disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025784
003      
CZ-PrNML
005      
20211026133517.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/febs.15528 $2 doi
035    __
$a (PubMed)32810928
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Tiemann-Boege, Irene $u Institute of Biophysics, Johannes Kepler University, Linz, Austria
245    10
$a Pathogenic postzygotic mosaicism in the tyrosine receptor kinase pathway: potential unidentified human disease hidden away in a few cells / $c I. Tiemann-Boege, T. Mair, A. Yasari, M. Zurovec
520    9_
$a Mutations occurring during embryonic development affect only a subset of cells resulting in two or more distinct cell populations that are present at different levels, also known as postzygotic mosaicism (PZM). Although PZM is a common biological phenomenon, it is often overlooked as a source of disease due to the challenges associated with its detection and characterization, especially for very low-frequency variants. Moreover, PZM can cause a different phenotype compared to constitutional mutations. Especially, lethal mutations in receptor tyrosine kinase (RTK) pathway genes, which exist only in a mosaic state, can have completely new clinical manifestations and can look very different from the associated monogenic disorder. However, some key questions are still not addressed, such as the level of mosaicism resulting in a pathogenic phenotype and how the clinical outcome changes with the development and age. Addressing these questions is not trivial as we require methods with the sensitivity to capture some of these variants hidden away in very few cells. Recent ultra-accurate deep-sequencing approaches can now identify these low-level mosaics and will be central to understand systemic and local effects of mosaicism in the RTK pathway. The main focus of this review is to highlight the importance of low-level mosaics and the need to include their detection in studies of genomic variation associated with disease.
650    _2
$a dítě $7 D002648
650    _2
$a fosfatidylinositol-3-kinasy třídy I $x genetika $x metabolismus $7 D058534
650    _2
$a embryo savčí $7 D004622
650    _2
$a fibrózní dysplazie polyostotická $x enzymologie $x genetika $x patologie $7 D005359
650    _2
$a exprese genu $7 D015870
650    _2
$a letální geny $7 D005804
650    12
$a zárodečné mutace $7 D018095
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    12
$a mozaicismus $7 D009030
650    _2
$a fenotyp $7 D010641
650    _2
$a Proteův syndrom $x enzymologie $x genetika $x patologie $7 D016715
650    _2
$a tyrosinkinasové receptory $x nedostatek $x genetika $7 D020794
650    _2
$a signální transdukce $7 D015398
650    _2
$a Sturgeův-Weberův syndrom $x enzymologie $x genetika $x patologie $7 D013341
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Mair, Theresa $u Institute of Biophysics, Johannes Kepler University, Linz, Austria
700    1_
$a Yasari, Atena $u Institute of Biophysics, Johannes Kepler University, Linz, Austria
700    1_
$a Zurovec, Michal $u Biology Centre of the Czech Academy of Sciences, Institute of Entomology, Ceske Budejovice, Czech Republic
773    0_
$w MED00008414 $t The FEBS journal $x 1742-4658 $g Roč. 288, č. 10 (2021), s. 3108-3119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32810928 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133523 $b ABA008
999    __
$a ok $b bmc $g 1714707 $s 1146291
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 288 $c 10 $d 3108-3119 $e 20200905 $i 1742-4658 $m The FEBS journal $n FEBS J $x MED00008414
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...